Risperidone LA-Paliperidone

From Psychiatrienet
Revision as of 14:01, 18 March 2022 by Ken (talk | contribs) (Created page with "{{Drugswitch | from = Risperidone_LA | to = Paliperidone | stop = {{Lastinjection}} | start = {{Start5week}} | info = {{caveQT}} | view = StopRisperLAStartOral.jpg }}")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
long acting
Type Antipsychotic
Group Atypical AP
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone
Type Antipsychotic
Group Atypical AP
Medscape Paliperidone
EMEA invega
PubChem 115237
PubMed Paliperidone
Kompas (Dutch) Paliperidone
Wikipedia Paliperidone

Switch medication from Risperidone_LA to Paliperidone.[1] [2]

Error creating thumbnail: File missing
Stop Risperidone_LA
  • Day 1: Last depot injection
Error creating thumbnail: File missing
Start Paliperidone
  • Day 35-38: approx. 25% of target dose
  • Day 39-42: approx. 50% of target dose
  • Day 43-46: approx. 75% of target dose
  • Day 47: target dose
Error creating thumbnail: File missing
More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[3]
Error creating thumbnail: File missing
— Risperidone_LA

Error creating thumbnail: File missing
— Paliperidone

  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.